| abstract |
(A) a compound of formula I or a tautomer thereof, a compound of formula II or a tautomer thereof, a compound of formula III or a tautomer thereof, a pharmaceutically acceptable salt of the compound, a pharmaceutically An RTK inhibitor selected from the group consisting of acceptable tautomeric salts thereof, or mixtures thereof, and (b) one or more such as tamoxifen, toremifene, fulvestrant, raloxifene or raloxifene hydrochloride A combination medicament comprising an anti-estrogen compound or a pharmaceutically acceptable salt thereof; use of such a combination in the treatment or prevention of a proliferative disorder; and a method of treating a subject suffering from a proliferative disorder; and A method of treating a subject suffering from a proliferative disorder, comprising administering a therapeutically effective amount of such a combination. |